GNPX genprex.com: Price-to-Projected Revenue Ratio
Genprex, Inc. (GNPX) management is strictly focused on validating the efficacy of its oncology drugs. The forward price-to-sales ratio demonstrates current dynamics, where the level captures the present state. Looking ahead, Genprex, Inc. (GNPX) plans the global expansion of REQORSA therapy and the development of the Oncoprex ecosystem for targeted gene delivery in lung tumors, aiming to secure a dominant position in the sector.
GNPX (Genprex Inc): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- business earnings and investment ratios data:
GNPX - Company Profit|Projected Future Earnings Genprex, Inc.|GNPX - Price to Earnings Ratio|Projected Price to Earnings Genprex, Inc|GNPX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Genprex Inc|GNPX - Operating profit before depreciation charges|Earnings per share for the last twelve months Genprex|GNPX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months genprex.com|GNPX - Earnings per share trend in current year|Expected earnings per share growth for next year Genprex, Inc.
- sales volume and revenue information:
Fundamental company valuation:Genprex (GNPX)
Investors view Genprex, Inc. (GNPX) as a high-risk asset with breakthrough potential in lung cancer therapy via the ONCOPREX system. Analyzing the current forward P/S ratio on GURU.Markets reveals the relationship between market capitalization and expected sales, reflecting the degree of market optimism priced in regarding the commercialization of gene therapy and determining the sensitivity of quotes to any changes in revenue forecasts.
Key competitors
Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|AAPG (Ascentage Pharma Corp) - Market Cap to Projected Revenue|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|Future Price to Revenue URGN (urogen.com)|Price-to-Projected Revenue Ratio Bicara Therapeutics|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|DCTH - Market Cap to Future Revenue Ratio|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|AURA: Market Cap to Projected Revenue|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS: Forward P/S Multiple|ACTU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|Market Cap to Projected Revenue HURA (TuHURA)|Forward P/S Multiple TARA|Forward Price-to-Revenue Multiple Fate Therapeutics Inc FATE|Aadi Bioscience - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio TScan Therapeutics Inc (TCRX)|Champions Oncology Corp - Forward P/S Multiple|Projected Price to Revenue XBiotech Inc. (XBIT)|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue OSTX|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Artiva - Future Price to Revenue|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Ltd.)|verupharma.com - Market Cap to Projected Revenue|Forward P/S Multiple TPST (Tempest Therapeutics, Inc.)|XLO - Forward Price-to-Revenue Multiple|Enochian BioSciences - Forward P/S Multiple|MURA - Forward P/S Multiple|kairospharma.com (KAPA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue OKUR|GDTC (CytoMed Therapeutics Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Curis Corp (CRIS)|Forward P/S Multiple APLM|THAR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Advanced Biomed ADVB|Forward Price to Sales CLDI|SBFM: Forward Price-to-Revenue Multiple|Forward Price to Sales XBIO (Xenetic Biosciences)|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|Forward Price-to-Revenue Multiple AONC|Forward P/S Multiple beigene.com|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|ELEV (elevationoncology.com) - Forward Price to Sales|Forward P/S Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Market Cap to Future Revenue Ratio|Notable Labs, Ltd. - Forward P/S Multiple|Projected Price to Revenue Viracta Therapeutics (VIRX)|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
